当前位置：
X-MOL 学术
›
Breast Cancer Res.
›
论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Correction to: Combination of mTORC1/2 inhibitor vistusertib plus fulvestrant in vitro and in vivo targets oestrogen receptor-positive endocrine-resistant breast cancer.
Breast Cancer Research ( IF 7.4 ) Pub Date : 2020-01-31 , DOI: 10.1186/s13058-020-1254-5 Sunil Pancholi 1 , Mariana Ferreira Leal 1 , Ricardo Ribas 1 , Nikiana Simigdala 1 , Eugene Schuster 1 , Sophie Chateau-Joubert 2 , Lila Zabaglo 1 , Margaret Hills 3 , Andrew Dodson 3 , Qiong Gao 1 , Stephen R Johnston 4 , Mitch Dowsett 3 , Sabina C Cosulich 5 , Elisabetta Marangoni 6 , Lesley-Ann Martin 1
Breast Cancer Research ( IF 7.4 ) Pub Date : 2020-01-31 , DOI: 10.1186/s13058-020-1254-5 Sunil Pancholi 1 , Mariana Ferreira Leal 1 , Ricardo Ribas 1 , Nikiana Simigdala 1 , Eugene Schuster 1 , Sophie Chateau-Joubert 2 , Lila Zabaglo 1 , Margaret Hills 3 , Andrew Dodson 3 , Qiong Gao 1 , Stephen R Johnston 4 , Mitch Dowsett 3 , Sabina C Cosulich 5 , Elisabetta Marangoni 6 , Lesley-Ann Martin 1
Affiliation
After publication of the original article [1], we were notified that an author's surname has been erroneously spelled. Elisabetta Maragoni's family name should be replaced with Marangoni.
中文翻译：
校正至：组合mTORC1 / 2抑制剂vistusertib和fulvestrant在体外和体内靶向雌激素受体阳性的内分泌耐药性乳腺癌。
在原始文章[1]发表后，我们被告知作者的姓氏拼写错误。Elisabetta Maragoni的姓氏应替换为Marangoni。
更新日期：2020-04-22
中文翻译：
校正至：组合mTORC1 / 2抑制剂vistusertib和fulvestrant在体外和体内靶向雌激素受体阳性的内分泌耐药性乳腺癌。
在原始文章[1]发表后，我们被告知作者的姓氏拼写错误。Elisabetta Maragoni的姓氏应替换为Marangoni。
京公网安备 11010802027423号